Crescent Sterling’s AbbVie ABBV Stock Holding History

Crescent Sterling’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.88M	Sell	14,848 -211	-1%	-$54.1K	3.19%	8
2026 Q2	$3.79M	Buy	15,059 +158	+1%	+$34K	3.39%	7
2026 Q1	$3.24M	Buy	14,901 +50	+0.3%	+$11.1K	3.14%	8
2025 Q4	$3.39M	Sell	14,851 -660	-4%	-$150K	3.48%	7
2025 Q3	$3.59M	Sell	15,511 -125	-0.8%	-$25.5K	3.78%	6
2025 Q2	$2.9M	Sell	15,636 -1,945	-11%	-$361K	3.25%	10
2025 Q1	$3.68M	Sell	17,581 -2,111	-11%	-$410K	3.78%	7
2024 Q4	$3.5M	Sell	19,692 -830	-4%	-$153K	3.59%	7
2024 Q3	$4.05M	Sell	20,522 -724	-3%	-$135K	3.86%	4
2024 Q2	$3.64M	Sell	21,246 -418	-2%	-$69.2K	3.49%	7
2024 Q1	$3.95M	Sell	21,664 -365	-2%	-$62.9K	3.6%	7
2023 Q4	$3.41M	Sell	22,029 -37	-0.2%	-$5.39K	3.41%	9
2023 Q3	$3.29M	Sell	22,066 -965	-4%	-$142K	3.48%	8
2023 Q2	$3.1M	Buy	23,031 +89	+0.4%	+$13.1K	2.94%	10
2023 Q1	$3.66M	Buy	22,942 +1,371	+6%	+$210K	3.55%	9
2022 Q4	$3.49M	Buy	+21,571	New	+$3.31M	3.74%	9

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Cardano Risk Management Rotterdam, Netherlands $18.2B AUM 38.97% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Crescent Sterling's ABBV Position: Q3 2026 in Review

Crescent Sterling reduced its AbbVie (ABBV) stake by 1.4% in Q3 2026, selling an estimated $54.1K and leaving 14,848 shares worth $3.88M. The position accounts for 3.19% of the portfolio, ranked #8.

Crescent Sterling first reported a position in ABBV in Q4 2022 and has held it in 16 quarters since. The position peaked at $4.05M in Q3 2024. 1,209 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Crescent Sterling held 14,848 shares of AbbVie worth $3.88M as of Q3 2026.
Crescent Sterling sold 211 AbbVie shares in Q3 2026, an estimated $54.1K.
AbbVie made up 3.19% of Crescent Sterling's portfolio in Q3 2026, its #8 holding.
Crescent Sterling first reported a position in AbbVie in Q4 2022 and has held it in 16 quarters since.
Crescent Sterling's AbbVie position peaked at $4.05M in Q3 2024.
1,209 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Crescent Sterling's 13F filing for Q3 2026, filed 16 Oct 2026.